Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMLQ71Y)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
CHEMBL2110370; GR 159897; 158848-32-9; 5-FLUORO-3-[2-[4-METHOXY-4-[[(R)-PHENYLSULPHINYL]METHYL]-1-PIPERIDINYL]ETHYL]-1H-INDOLE; GR-159897; GR-159,897; GTPL2115; CHEBI:92912; MolPort-023-276-059; ZINC7999073; BDBM50212987; AKOS025147300; AKOS024456505; NCGC00381706-02; KB-309739; SR-01000597395; SR-01000597395-1; 5-fluoro-3-[2-[4-methoxy-4-[[(R)-phenylsulfinyl]methyl]piperidin-1-yl]ethyl]-1H-indole; 5-Fluoro-3-[2-[4-methoxy-4-[[ -phenylsulphinyl]methyl]-1-piperidinyl]ethyl]-1H-indole
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Bone
Osteosarcoma
Breast
Breast adenocarcinoma
Colon
Colorectal adenocarcinoma
Hematopoietic system
Normal
Kidney
Normal (Immortalized)
Liver
Hepatoblastoma
Lung
Lung adenocarcinoma
Non-small cell lung carcinoma
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
